Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(43%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_3
4
57%
Ph phase_4
1
14%

Phase Distribution

0

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
4(57.1%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting3
Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (28.6%)
Phase 34 (57.1%)
Phase 41 (14.3%)

Trials by Status

recruiting343%
terminated114%
completed229%
unknown114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_2

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

NCT07018622
recruitingphase_3

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

NCT07295223
recruitingphase_3

Epicardial Cardiac Fat-CT (EPIC-CT)

NCT07297589
completedphase_3

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

NCT04965935
completedphase_4

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)

NCT04004793
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07018622Phase 2

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

Recruiting
NCT07295223Phase 3

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

Recruiting
NCT07297589Phase 3

Epicardial Cardiac Fat-CT (EPIC-CT)

Recruiting
NCT04965935Phase 3

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

Completed
NCT04004793Phase 4

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)

Completed
NCT04860011Phase 3

DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance

Unknown
NCT03537131Phase 2

Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7